TY - JOUR
T1 - Strategic nanocarriers to control neurodegenerative disorders
T2 - Concept, challenges, and future perspective
AU - Ashique, Sumel
AU - Afzal, Obaid
AU - Yasmin, Sabina
AU - Hussain, Afzal
AU - Altamimi, Mohammad A.
AU - Webster, Thomas J.
AU - Altamimi, Abdulmalik S.A.
N1 - Publisher Copyright:
© 2023 Elsevier B.V.
PY - 2023/2/25
Y1 - 2023/2/25
N2 - Various neurodegenerative diseases (parkinson, huntington, alzheimer, and amyotrophic lateral sclerosis) are becoming serious global health challenges. Despite various treatment options, successful delivery and effective outcomes have been challenged with several physiological-anatomical barriers, formulation related issues, post-administration hurdles, regulatory constraints, physical hurdles, environmental issues, and safety concern. In the present review, we addressed a brief understanding of pathological and normal condition of blood brain barrier (BBB), rational for brain delivery using nanocarriers, major challenges, advantages of nanomedicine, critical aspects of nanomedicine to translate from bed to clinics, and strategic approaches for improved delivery across BBB. The review addressed various mechanistic perspective for delivery of drug loaded nanocarriers across BBB. Moreover, several reports have been published wherein phytomedicine, exosomes, magnetic nanopartilces, functionalized nanocarriers, cationic nanopartilces, and nano-phytomedicine were investigated for remarkable improvement in neurological disorders. These findings are informative for healthcare professionals, researchers, and scientists working in the domains. The successful application and convincing outcomes of nanomedicines were envisaged with clinical trials conducted on various drugs intended to control neurological disorders (NDs). Conclusively, the review addressed comprehensive findings on various aspects of drug loaded nanocarrier delivery across BBB, considerable risks, potential therapeutic benefits, clinical trial based outcomes, and recent advances followed by future perspectives.
AB - Various neurodegenerative diseases (parkinson, huntington, alzheimer, and amyotrophic lateral sclerosis) are becoming serious global health challenges. Despite various treatment options, successful delivery and effective outcomes have been challenged with several physiological-anatomical barriers, formulation related issues, post-administration hurdles, regulatory constraints, physical hurdles, environmental issues, and safety concern. In the present review, we addressed a brief understanding of pathological and normal condition of blood brain barrier (BBB), rational for brain delivery using nanocarriers, major challenges, advantages of nanomedicine, critical aspects of nanomedicine to translate from bed to clinics, and strategic approaches for improved delivery across BBB. The review addressed various mechanistic perspective for delivery of drug loaded nanocarriers across BBB. Moreover, several reports have been published wherein phytomedicine, exosomes, magnetic nanopartilces, functionalized nanocarriers, cationic nanopartilces, and nano-phytomedicine were investigated for remarkable improvement in neurological disorders. These findings are informative for healthcare professionals, researchers, and scientists working in the domains. The successful application and convincing outcomes of nanomedicines were envisaged with clinical trials conducted on various drugs intended to control neurological disorders (NDs). Conclusively, the review addressed comprehensive findings on various aspects of drug loaded nanocarrier delivery across BBB, considerable risks, potential therapeutic benefits, clinical trial based outcomes, and recent advances followed by future perspectives.
KW - Critical aspects
KW - Nanomedicines
KW - Neurodegenerative diseases (NDs)
KW - Phytomedicines and clinical trials
KW - Several challenges
KW - Strategic approaches
UR - http://www.scopus.com/inward/record.url?scp=85147029541&partnerID=8YFLogxK
U2 - 10.1016/j.ijpharm.2023.122614
DO - 10.1016/j.ijpharm.2023.122614
M3 - Review article
C2 - 36646255
AN - SCOPUS:85147029541
SN - 0378-5173
VL - 633
JO - International Journal of Pharmaceutics
JF - International Journal of Pharmaceutics
M1 - 122614
ER -